Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Kidney Research and Clinical Practice ; : 159-166, 2017.
Article in English | WPRIM | ID: wpr-48166


BACKGROUND: Mizoribine (MZR) is an immunosuppressive drug used in Japan for treating patients with lupus nephritis and nephrotic syndrome and has been also reportedly effective in patients with immunoglobulin A (IgA) nephropathy. However, to date, few randomized control studies of MZR are performed in patients with IgA nephropathy. Therefore, this prospective, open-label, randomized, controlled trial aimed to investigate the efficacy and safety of adding MZR to standard treatment in these patients, and was conducted between April 1, 2009, and March 31, 2016, as a multicenter study. METHODS: Patients were randomly assigned (1:1) to receiving standard treatment plus MZR (MZR group) or standard treatment (control group). MZR was administered orally at a dose of 150 mg once daily for 12 months. RESULTS: Primary outcomes were the percentage reduction in urinary protein excretion from baseline and the rate of patients with hematuria disappearance 36 months after study initiation. Secondary outcomes were the rate of patients with proteinuria disappearance, clinical remission rate, absolute changes in estimated glomerular filtration rate from baseline, and the change in daily dose of prednisolone. Forty-two patients were randomly assigned to MZR (n = 21) and control groups (n = 21). Nine patients in MZR group and 15 patients in the control group completed the study. No significant differences were observed between the two groups with respect to primary and secondary outcomes. CONCLUSION: The addition of MZR to standard treatment has no beneficial effect on reducing urinary protein excretion and hematuria when treating patients with IgA nephropathy.

Humans , Glomerular Filtration Rate , Glomerulonephritis, IGA , Hematuria , Immunoglobulin A , Immunoglobulins , Japan , Lupus Nephritis , Nephrotic Syndrome , Prednisolone , Prospective Studies , Proteinuria
Japanese Journal of Cardiovascular Surgery ; : 359-362, 2002.
Article in Japanese | WPRIM | ID: wpr-366808


Celiac artery aneurysm (CAA) is very rare. We report a case of CAA with type IIIb aortic dissection (DA) which was treated surgically. A 60-year-old man who had an abnormal enlargement of the aorta on abdominal ultrasonography was admitted to our hospital. Angiography and CT scan revealed CAA with type IIIb DA. His general condition was stable and surgery was performed electively. The CAA was exposed through a median laparotomy. It was found to be about 3cm in diameter. As vascular reconstruction seemed difficult and the proper hepatic artery showed good pulsation after clamping the common hepatic artery, we decided to perform celiac artery aneurysmectomy without vascular reconstruction. Except for transient liver dysfunction, there was no other complication and he was discharged on the 24th postoperative day. During surgery for CAA, when collateral perfusion from the SMA to the liver is adequate, it seems that vascular reconstruction is not always necessary as shown by this case.

Japanese Journal of Cardiovascular Surgery ; : 265-267, 2001.
Article in Japanese | WPRIM | ID: wpr-366700


A 57-year-old man suffered hemoptysis during an examination for gastric carcinoma. Enhanced computed tomography demonstrated rupture of a thoracic aortic aneurysm to the left pulmonary lower lobe. The lateral segment of the liver was atrophic due to intrahepatic cholelithiasis. Emergency operation was performed after he was transferred to our hospital. The thoracic aorta was reconstructed using a temporary bypass and the pulmonary left lower lobe was resected. The omentum was mobilized and used to cover the prosthesis and bronchial stump. The gastric carcinoma and intrahepatic cholelithiasis with biliary stones in the common bile duct were treated in the next procedure. The pathologic examination revealed lymph node metastasis; thus this operation was recognized to be absolutely noncurative. The treatment of cardiovascular disease concomitant with malignancy remains controversial. The strategy to treat such patients is discussed in this report.